MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.45
+0.31
+1.21%
Opening 11:28 03/08 EST
OPEN
25.22
PREV CLOSE
25.15
HIGH
25.92
LOW
25.14
VOLUME
173.54K
TURNOVER
--
52 WEEK HIGH
31.99
52 WEEK LOW
13.12
MARKET CAP
1.35B
P/E (TTM)
10.56
1D
5D
1M
3M
1Y
5Y
Apomorphine Hydrochloride Market to see Huge Growth by 2026 | US WorldMeds, Ever Pharma, Evolan Pharma, Sunovion
Mar 05, 2021 (Market Insight Reports) -- Apomorphine Hydrochloride Market Comprehensive Study is an expert and top to bottom investigation on the momentum...
Market Insight Reports · 3d ago
DJ Supernus Pharmaceuticals, Inc. CEO Jack Khattar on Q4 2020 Results -- Earnings Call Transcript >SUPN
Dow Jones · 02/28 06:59
8-K: SUPERNUS PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- false000135657600013565762021-02-252021-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/27 07:37
Supernus to Present at Cowen Healthcare Conference
ROCKVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Ja...
GlobeNewswire · 02/26 14:00
The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25)
Benzinga · 02/26 13:16
Supernus Pharmaceuticals reports Q4 results
Supernus Pharmaceuticals (SUPN): Q4 GAAP EPS of $0.57.Revenue of $143.56M (+42.9% Y/Y)Press Release
Seekingalpha · 02/25 21:45
Supernus Pharmaceuticals Sees 2021 Rev $550M-$580M >SUPN
Supernus Pharmaceuticals Sees 2021 Rev $550M-$580M >SUPN
Dow Jones · 02/25 21:06
BRIEF-Supernus Reports Q4 And Full Year 2020 Financial Results
reuters.com · 02/25 21:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SUPN. Analyze the recent business situations of Supernus Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SUPN stock price target is 30.75 with a high estimate of 35.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 411
Institutional Holdings: 62.38M
% Owned: 117.99%
Shares Outstanding: 52.87M
TypeInstitutionsShares
Increased
73
3.69M
New
58
68.92K
Decreased
83
2.36M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.19%
Pharmaceuticals & Medical Research
+1.13%
Key Executives
Chairman/Independent Director
Charles Newhall
President/Chief Executive Officer/Secretary/Director
Jack Khattar
Chief Financial Officer/Executive Vice President
James Kelly
Senior Vice President/Chief Scientific Officer
Padmanabh Bhatt
Senior Vice President
Tami Martin
Senior Vice President
Frank Mottola
Independent Director
Carrolee Barlow
Independent Director
Georges Gemayel
Independent Director
Frederick Hudson
Independent Director
John Siebert
No Data
  • All
  • Financials
  • Insiders
More
About SUPN
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Webull offers kinds of Supernus Pharmaceuticals Inc stock information, including NASDAQ:SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.